Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · American Healthcare REIT (AHR)

American Healthcare REIT CEO Danny Prosky takes medical leave; Jeffrey Hanson named interim CEO

Neutral Impact 4 of 5 leadership Written later

American Healthcare REIT (NYSE: AHR) said its CEO and President, Danny Prosky, is on medical leave effective February 3, 2026, following a recent medical event. The board appointed Chairman Jeffrey T. Hanson, who was CEO from 2015 to 2021, as interim CEO and President effective the same date. The filing does not address financial results or guidance, but the leadership change is significant for shareholders during the interim period.

Key points

  • Danny Prosky, CEO, President and director, began a medical leave of absence effective February 3, 2026
  • Jeffrey T. Hanson, Chairman of the Board and CEO from 2015 to 2021, is Interim CEO and President effective February 3, 2026
  • The company said its senior leadership team is long-tenured and will work with Hanson to ensure continuity of operations
  • The press release was issued February 4, 2026 (Exhibit 99.1)

The filing

CompanyAmerican Healthcare REIT (AHR)
Form8-K, current report
Filed with the SECFeb 4, 2026, 4:32 PM ET
Accession number0001193125-26-037696

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:12 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.